Skip to main content

Staff Profile

Professor Camille Carroll

Professor of Clinical Neuroscience

  • Email: camille.carroll@ncl.ac.uk
  • Address: Translational and Clinical Research Institute
    Faculty of Medical Sciences
    Newcastle University
    Clinical Ageing Research Unit
    Campus for Ageing and Vitality
    Newcastle upon Tyne
    NE4 5PL
Background

I am Professor of Clinical Neuroscience at the Translational and Clinical Research Institute at Newcastle and Faculty of Health, University of Plymouth. I am Honorary Consultant Neurologist at University Hospitals Plymouth NHS Trust. I undertook preclinical medical training at the University of Manchester, where I also completed an intercalated PhD (1994) investigating NMDA receptor antagonists in models of Parkinson's disease (PD). I completed clinical training at the University of Oxford in 1997 and undertook specialist neurology training in the South West and West Midlands. I was awarded an MRC post-doctoral clinical research training fellowship in 2007, enabling me to develop my research interest in investigating neuroprotection in Parkinson's disease. 


I am joint Clinical Director of the Parkinson’s Excellence Network in the UK and have been internationally recognized for my patient-centred approach, broadening the opportunity for Parkinson’s research and improving support for patient care and self-management. I was NIHR Clinical Research Network National Specialty Lead for Neurodegenerative Diseases (2017-2024), overseeing a balanced clinical trial portfolio in neurodegenerative disorders and led the NIHR Remote Methods of Trial Delivery project.


Within University Hospitals Plymouth NHS Trust, I led the development of the Parkinson’s disease service, which won Parkinson's Excellence Network Awards in 2017 and 2019, BMJ Award Highly Commended for Digital Innovation in 2021 and the Bright Ideas for Health Award for Digital Innovation in 2024.


I co-chair the international Linked Clinical Trials Committee (Cure Parkinson's), am a founding co-deputy chair of the Parkinson's Clinical Studies Group, a member of the College of Experts (Parkinson's UK), co-chair of the International Movement Disorder Society Patient and Carer Committee, Member EAN/MDS-ES PD Guidelines Task Force, member of Association of British Neurologists Movement Disorders Advisory Group and Associate Editor Journal of Parkinson's Disease.

Research

My research is focused on disease modification and the use of digital health technologies for monitoring and personalised care in Parkinson’s. I was the chief investigator of a multi-centre clinical trial of simvastatin as a disease modifying agent in Parkinson’s disease (PD STAT), and am a co-investigator of the Exenatide-PD3 trial. One of my major interests is innovation in trial design and delivery, aiming to increase efficiency and ensure that trials are more inclusive of under-served populations. With Prof. Tom Foltynie (UCL), I co-lead the the Edmond J Safra ACT-PD initiative, a multi-professional consortium developing a multi-arm, multi-stage trial platform for disease modifying interventions in Parkinson’s, which will transform the disease-modifying trial landscape in the UK.


In collaboration with Prof. Edward Meinert, I am creating digital tools to support patient self-management and digitally-enabled care, embedded in innovative care pathways that have been co-created with patients and multiple professionals. The development, iteration and evaluation of these novel approaches to care will enable translation to other long-term conditions and neurodegenerative diseases.


I act as principal and UK lead investigator for commercial interventional trials in Parkinson's disease, and am a member/chair of several trial steering and data monitoring committees.







Publications

  • Articles

    • Devos D, Rascol O, Meissner WG, Foubert-Samier A, Lewis S, Tranchant C, Anheim M, Maltete D, Remy P, Eggert K, Pape H, Geny C, Couratier P, Carroll C, Sheridan R, Burn D, Pavese N, Raw J, Berg D, Suchowersky O, Kalia LV, Evans A, Drapier S, Danaila T, Schnitzler A, Corvol J-C, Defer G, Temin NT, Fradette C, Tricta F, Moreau C. Therapeutic modalities of deferiprone in Parkinson's disease: SKY and EMBARK studies. Journal of Parkinson's Disease 2025, 15(1), 72-86.
    • Ferreira JJ, Rascol O, Stocchi F, Antonini A, Moreira J, Castilla-Fernandez G, Rocha J-F, Holenz J, Poewe W, Marechal E, Bergmans B, De Weweire M, Manolova-Mancheva T, Bosilkov A, Haralanov L, Milanov I, Ikonomov R, Kirilov K, Naydenov V, Izmailov A, Traykov L, Balaz M, Pazdera L, Bajacek M, Skoda O, Bartlova L, Talab R, Hort J, Valis M, Ehler E, Rascol O, Drapier S, Defebvre L, Thobois S, Castelnovo G, Toenges L, Krause P, Falkenburger B, Schwarz J, Klostermann F, Schnitzler A, Volonte MA, Tessitore A, Barone P, Colosimo C, Buonaura GC, Centonze D, De Pandis MF, Vacca L, Antonini A, Trzebinska-Frydrychowska E, Siuda J, Machowski J, Ilkowski J, Nastaj M, Rudzinska-Bar M, Kasprzyk-Galon K, Grudniak M, Ferreira JJ, Gago MF, Mendes A, Dedic SK, Svetel M, Knezevic Z, Jovic J, Rivera PM, Cristobal GL, Martinez EB, Ballestero TD, Serra FV, Krupinski J, Pons NC, Garriga MC, Morales EA, Vara JH, Cakmur R, Hanagasi H, Uslu F, Dogu O, Elibol B, Carroll C, Walker R, Ledingham D, Sammler E, Marshall V, Pasiura I, Buchakchyiska N, Dziak L, Moskovko S, Sanotskyy Y, Kozyolkin O, Slobodin T. Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial. European Journal of Neurology 2025, 32(1), e16420.
    • Vijiaratnam N, Girges C, Auld G, McComish R, King A, Skene SS, Hibbert S, Wong A, Melander S, Gibson R, Matthews H, Dickson J, Carroll C, Patrick A, Inches J, Silverdale M, Blackledge B, Whiston J, Hu M, Welch J, Duncan G, Power K, Gallen S, Kerr J, Chaudhuri KR, Batzu L, Rota S, Jabbari E, Morris H, Limousin P, Greig N, Li Y, Libri V, Gandhi S, Athauda D, Chowdhury K, Foltynie T. Exenatide once a week versus placebo as a potential disease modifying treatment for people with Parkinson’s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. The Lancet 2025, 405(10479), 627-636.
    • Hall AM, Allgar V, Carroll CB, Meinert E. Digital health technologies and self-efficacy in Parkinson's: a scoping review. BMJ Open 2025, 15(1), e088616.
    • Boege S, Milne-Ives M, Meinert E, Carroll C. Self-Management Systems for Patients and Clinicians in Parkinson Care: Protocol for an Integrated Scoping Review, Product Search, and Evaluation. JMIR Research Protocols 2024, 13, e58845.
    • Espay AJ, Stocchi F, Pahwa R, Albanese A, Ellenbogen A, Ferreira JJ, Giladi N, Gurevich T, Hassin-Baer S, Hernandez-Vara J, Isaacson SH, Kieburtz K, LeWitt PA, Lopez-Manzanares L, Olanow CW, Poewe W, Sarva H, Yardeni T, Adar L, Salin L, Lopes N, Sasson N, Case R, Rascol O, Afshari M, Amelin A, Arkadir D, Badarny S, Balaguer Martinez E, Bogucki A, Boyd J, Buyan Dent L, Carroll C, Chaudhuri KR, Cooney J, Corbille A-G, Danaila T, De Pandis MF, Dethy S, Dhall R, Djaldetti R, Durif F, Flitman S, Freire Alvarez E, Goudreau J, Grandas Perez F, Isa A, Juncos JL, Kanchana S, Klodowska-Duda G, Koziorowski D, Kulisevsky Bojarski J, Lopez Lozano J, Luo L, Lytvynenko N, Marconi R, Marques A-R, Martinez Castrillo JC, Martinez Torres I, Mentreddi A, Mir Rivera P, Moskovko S, Neryanova Y, Onofrj M, Ostrem J, Pacchetti C, Pavese N, Pellicano C, Revuelta G, Rodrigues AM, Rodriguez R, Rudzinska M, Sarwar N, Schwartzbard J, Scorr L, Slevin J, Slobodin T, Spalletta G, Tagliati M, Tai Y, Tessitore A, Valkovic P, Verhagen L, Vostrikova E, Yahalom G, Zalyalova Z, Zarubova K, Zhukova I. Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial. The Lancet Neurology 2024, 23(5), 465-476.
    • Kehagia AA, Chowienczyk S, Helena Van Velthoven M, King E, North T, Shenton D, Abraham J, Langley J, Partridge R, Ankeny U, Gorst T, Edwards E, Whipps S, Batup M, Rideout J, Swabey M, Inches J, Bentley S, Gilbert G, Carroll C. Real-World Evaluation of the Feasibility, Acceptability and Safety of a Remote, Self-Management Parkinson's Disease Care Pathway: A Healthcare Improvement Initiative. Journal of Parkinson's Disease 2024, 14(1), 197-208.
    • Sauerbier A, Herberg J, Stopic V, Loehrer PA, Ashkan K, Rizos A, Jost ST, Petry-Schmelzer JN, Gronostay A, Schneider C, Visser-Vandewalle V, Evans J, Nimsky C, Fink GR, Antonini A, Martinez-Martin P, Silverdale M, Weintraub D, Schrag A, Ray Chaudhuri K, Timmermann L, Dafsari HS, Adler C, Bhidayasiri R, Borghammer P, Barone P, Brooks DJ, Brown R, Cantillon M, Carroll C, Coelho M, Falup-Pecurariu C, Henriksen T, Hu M, Jenner P, Jeon B, Kramberger M, Kumar P, Kurtis M, Leta V, Lewis S, Litvan I, Lyons K, Martino D, Masellis M, Mochizuki H, Morley JF, Nirenberg M, Odin P, Pagonabarraga J, Panicker J, Pavese N, Pekkonen E, Postuma R, Rodriguez Violante M, Rosales R, Schapira A, Simuni T, Stocchi F, Storch A, Subramanian I, Tagliati M, Tinazzi M, Toledo J, Tsuboi Y, Walker R. Predictors of short-term anxiety outcome in subthalamic stimulation for Parkinson’s disease. npj Parkinson's Disease 2024, 10(1), 114.
    • Zeissler M-L, Bakshi N, Bartlett M, Batla A, Byrom D, Chapman R, Collins S, Cowd E, Deeson E, Ellis-Doyle R, Forbes J, Gonzalez-Robles C, Jewell A, Lane EL, LaPelle NR, Martin K, Matthews H, Miller L, Mills G, Morgan A, Parry M, Pushparatnam K, Ratcliffe N, Salathiel D, Scurfield P, Siu C, Whipps S, Wonnacott S, Foltynie T, Carroll CB, McFarthing K. Patient and Public Involvement and Engagement in the Development of a Platform Clinical Trial for Parkinson's Disease: An Evaluation Protocol. Journal of Parkinson's Disease 2024, 14(4), 809-821.
    • Kim JJ, Vitale D, Otani DV, Lian MM, Heilbron K, Aslibekyan S, Auton A, Babalola E, Bell RK, Bielenberg J, Bryc K, Bullis E, Cannon P, Coker D, Partida GC, Dhamija D, Das S, Elson SL, Eriksson N, Filshtein T, Fitch A, Fletez-Brant K, Fontanillas P, Freyman W, Granka JM, Hernandez A, Hicks B, Hinds DA, Jewett EM, Jiang Y, Kukar K, Kwong A, Lin K-H, Llamas BA, Lowe M, McCreight JC, McIntyre MH, Micheletti SJ, Moreno ME, Nandakumar P, Nguyen DT, Noblin ES, O'Connell J, Petrakovitz AA, Poznik GD, Reynoso A, Schloetter M, Schumacher M, Shastri AJ, Shelton JF, Shi J, Shringarpure S, Su QJ, Tat SA, Tchakoute CT, Tran V, Tung JY, Wang X, Wang W, Weldon CH, Wilton P, Wong CD, Iwaki H, Lake J, Solsberg CW, Leonard H, Makarious MB, Tan E-K, Singleton AB, Bandres-Ciga S, Noyce AJ, Gatto EM, Kauffman M, Khachatryan S, Tavadyan Z, Shepherd CE, Hunter J, Kumar K, Ellis M, Renteria ME, Koks S, Zimprich A, Schumacher-Schuh AF, Rieder C, Awad PS, Tumas V, Camargos S, Fon EA, Monchi O, Fon T, Galleguillos BP, Miranda M, Bustamante ML, Olguin P, Chana P, Tang B, Shang H, Guo J, Chan P, Luo W, Arboleda G, Orozc J, del Rio MJ, Hernandez A, Salama M, Kamel WA, Zewde YZ, Brice A, Corvol J-C, Westenberger A, Illarionova A, Mollenhauer B, Klein C, Vollstedt E-J, Hopfner F, Hoglinger G, Madoev H, Trinh J, Junker J, Lohmann K, Lange LM, Sharma M, Groppa S, Gasser T, Fang Z-H, Akpalu A, Xiromerisiou G, Hadjigorgiou G, Dagklis I, Tarnanas I, Stefanis L, Stamelou M, Dadiotis E, Medina A, Chan GH-F, Ip N, Cheung NY-F, Chan P, Zhou X, Kishore A, Divya KP, Pal P, Kukkle PL, Rajan R, Borgohain R, Salari M, Quattrone A, Valente EM, Parnetti L, Avenali M, Schirinzi T, Funayama M, Hattori N, Shiraishi T, Karimova A, Kaishibayeva G, Shambetova C, Kruger R, Tan AH, Ahmad-Annuar A, Norlinah MI, Murad NAA, Azmin S, Lim S-Y, Mohamed W, Tay YW, Martinez-Ramirez D, Rodriguez-Violante M, Reyes-Perez P, Tserensodnom B, Ojha R, Anderson TJ, Pitcher TL, Sanyaolu A, Okubadejo N, Ojo O, Aasly JO, Pihlstrom L, Tan M, Ur-Rehman S, Veliz-Otani D, Cornejo-Olivas M, Doquenia ML, Rosales R, Vinuela A, Iakovenko E, Mubarak BA, Umair M, Amod F, Carr J, Bardien S, Jeon B, Kim YJ, Cubo E, Alvarez I, Hoenicka J, Beyer K, Perinan MT, Pastor P, El-Sadig S, Brolin K, Zweier C, Tinkhauser G, Krack P, Lin C-H, Wu H-C, Kung P-J, Wu R-M, Wu Y, Amouri R, Sassi SB, Basak AN, Genc G, Cakmak OO, Ertan S, Martinez-Carrasco A, Schrag A, Schapira A, Carroll C, Bale C, Grosset D, Stafford EJ, Houlden H, Morris HR, Hardy J, Mok KY, Rizig M, Wood N, Williams N, Okunoye O, Lewis PA, Kaiyrzhanov R, Weil R, Love S, Stott S, Jasaityte S, Dey S, Obese V, Espay A, O'Grady A, Sobering AK, Siddiqi B, Casey B, Fiske B, Jonas C, Cruchaga C, Pantazis CB, Comart C, Wegel C, Hall D, Hernandez D, Shiamim E, Riley E, Faghri F, Serrano GE, Chen H, Mata IF, Sarmiento IJK, Williamson J, Jankovic J, Shulman J, Solle JC, Murphy K, Nuytemans K, Kieburtz K, Markopoulou K, Marek K, Levine KS, Chahine LM, Ibanez L, Screven L, Ruffrage L, Shulman L, Marsili L, Kuhl M, Dean M, Koretsky M, Puckelwartz MJ, Inca-Martinez M, Louie N, Mencacci NE, Albin R, Alcalay R, Walker R, Chowdhury S, Dumanis S, Lubbe S, Xie T, Foroud T, Beach T, Sherer T, Song Y, Nguyen D, Nguyen T, Atadzhanov M, Blauwendraat C, Nalls MA, Foo JN, Mata I. Multi-ancestry genome-wide association meta-analysis of Parkinson’s disease. Nature Genetics 2024, 56(1), 27-36.
    • Dobreva I, Thomas J, Marr A, O'Connell R, Roche M, Hannaway N, Dore C, Rose S, Liu K, Bhome R, Baldwin-Jones S, Roberts J, Archibald N, Alston D, Amar K, Edwards E, Foley J, Haunton V, Henderson E, Jha A, Lindop F, Magee C, Massey L, Ruiz-Mendoza E, Mohamed B, Patterson K, Ramaswamy B, Schrag A, Silverdale M, Suarez-Gonzalez A, Subramanian I, Foltynie T, Williams-Gray C, Yarnall AJ, Carroll C, Bale C, Hugill C, Weil R. Improving conversations about Parkinson’s dementia. Movement Disorders Clinical Practice 2024, 11(7), 814-824.
    • Gonzalez-Robles C, Bartlett M, Burnell M, Clarke CS, Haar S, Hu MT, Huxford B, Jha A, Lawton M, Noyce A, Piccini P, Pushparatnam K, Rochester L, Siu C, van Wamelen D, Williams-Gray CH, Zeissler M-L, Zetterberg H, Carroll CB, Foltynie T, Weil RS, Schrag A. Embedding Patient Input in Outcome Measures for Long-Term Disease-Modifying Parkinson Disease Trials. Movement Disorders 2024, 39(2), 433-438.
    • Fabbri M, Rascol O, Foltynie T, Carroll C, Postuma RB, Porcher R, Corvol JC. Advantages and Challenges of Platform Trials for Disease Modifying Therapies in Parkinson's Disease. Movement Disorders 2024, 39(9), 1468-1477.
    • Khanna A, Adams J, Antoniades C, Bloem BR, Carroll C, Cedarbaum J, Cosman J, Dexter DT, Dockendorf MF, Edgerton J, Gaetano L, Goikoetxea E, Hill D, Horak F, Izmailova ES, Kangarloo T, Katabi D, Kopil C, Lindemann M, Mammen J, Marek K, McFarthing K, Mirelman A, Muller M, Pagano G, Peterschmitt MJ, Ren J, Rochester L, Sardar S, Siderowf A, Simuni T, Stephenson D, Swanson-Fischer C, Wagner JA, Jones GB. Accelerating Parkinson’s Disease drug development with federated learning approaches. npj Parkinson's Disease 2024, 10(1), 225.
    • Collett J, Lawrie S, Bromley S, Harling P, Reed A, Brusco N, Coe S, Coebergh J, Carroll C, Roberts HC, Hu MT, Dawes H. A programme evaluation of 'First Steps': A peer-conceived, developed and led self-management intervention for people after a Parkinson's diagnosis. Clinical Rehabilitation 2024, 38(3), 403-413.
    • Gonzalez-Robles C, Weil RS, Van Wamelen D, Bartlett M, Burnell M, Clarke CS, Hu MT, Huxford B, Jha A, Lambert C, Lawton M, Mills G, Noyce A, Piccini P, Pushparatnam K, Rochester L, Siu C, Williams-Gray CH, Zeissler M-L, Zetterberg H, Carroll CB, Foltynie T, Schrag A. Outcome Measures for Disease-Modifying Trials in Parkinson's Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative. Journal of Parkinson's Disease 2023, 13(6), 1013-1035.
    • Zeissler M-L, Boey T, Chapman D, Rafaloff G, Dominey T, Raphael KG, Buff S, Pai HV, King E, Sharpe P, O'Brien F, Carroll CB. Investigating trial design variability in trials of disease-modifying therapies in Parkinson’s disease: a scoping review protocol. BMJ Open 2023, 13(12), e071641.
    • Chapman R, Zeissler M-L, Meinert E, Mullin S, Whipps S, Whipps J, Hockey K, Hockey P, Carroll CB. Incorporating usability evaluation into iterative development of an online platform to support research participation in Parkinson's disease: A mixed methods protocol. BMJ Open 2023, 13(12), e078638.
    • Hall AM, Aroori S, Carroll CB, Meinert E, Allgar V. Impact of digital technologies on self-efficacy in people with Parkinson's: a scoping review protocol. BMJ Open 2023, 13(3), e069929.
    • Rizig M, Bandres-Ciga S, Makarious MB, Ojo OO, Crea PW, Abiodun OV, Levine KS, Abubakar SA, Achoru CO, Vitale D, Adeniji OA, Agabi OP, Koretsky MJ, Agulanna U, Hall DA, Akinyemi RO, Xie T, Ali MW, Shamim EA, Ani-Osheku I, Padmanaban M, Arigbodi OM, Standaert DG, Bello AH, Dean MN, Erameh CO, Elsayed I, Farombi TH, Okunoye O, Fawale MB, Billingsley KJ, Imarhiagbe FA, Jerez PA, Iwuozo EU, Baker B, Komolafe MA, Malik L, Nwani PO, Daida K, Nwazor EO, Miano-Burkhardt A, Nyandaiti YW, Fang Z-H, Obiabo YO, Kluss JH, Odeniyi OA, Hernandez DG, Odiase FE, Tayebi N, Ojini FI, Sidranksy E, Onwuegbuzie GA, D'Souza AM, Osaigbovo GO, Berhe B, Osemwegie N, Reed X, Oshinaike OO, Leonard HL, Otubogun FM, Alvarado CX, Oyakhire SI, Ozomma SI, Samuel SC, Taiwo FT, Wahab KW, Zubair YA, Iwaki H, Kim JJ, Morris HR, Hardy J, Heilbron K, Norcliffe-Kaufmann L, Okubadejo N, Ojo O, Abiodun O, Achoru C, Agabi O, Akinyemi R, Ali M, Arigbodi O, Bello A, Erameh C, Farombi T, Fawale M, Imarhiagbe F, Iwuozo E, Komolafe M, Nwani P, Nwazor E, Nyandaiti Y, Obiabo Y, Odeniyi O, Odiase F, Ojini F, Onwuegbuzie G, Osaigbovo G, Oshinaike O, Otubogun F, Oyakhire S, Ozomma S, Samuel S, Taiwo F, Wahab K, Zubair Y, Gams Massi D, Gueumekane Bila lamou E, Njamnshi Nfor L, Magnerou MA, Fogang Fogoum Y, Shalash A, El-FawaI H, Khedr E, Fawi G, A Eltantawi M, Salama M, El-Jaafary S, Hamed S, Tafesse Mengesha A, Alemayehu Ayele B, Melka Oda D, Zenebe Zewde Y, Debebe Gelan Y, AkpaIu A, Charway-Felli A, Stephen Sarfo F, Adjei P, Obese V, Bocoum A, Koita A, Oumar Guinto C, Coulibaly T, Maiga Y, Kone Z, Bell A, Adebowale AA, Akpekpe J, lyagba A, Wulgo AM, Arabambi B, Agu C, Dike F, Ishola I, Abiodun K, Ekenze O, Agabi Osigwe P, Balarabe S, Abubakar S, Williams U, Fall M, Mamadou Diop A, Hilaire Dominique ET, Mochan A, Modi G, Dindayal S, Ali Awadelkareem E, Dahawi M, Awadelkareem MA, Misbah S, Mushengez B, Kimambo H, Msango L, Adebayo P, OKeng K, Diekker M, URassa S, Gouider R, Ben Djebara M, Gargouri A, Kacem I, Nasri A, Mrabet S, Sghaier I, Mkada I, Atadzhanov M, Chishimba L, Jama F, Houlden H, Singleton A, Nalls M, Shamim E, Jonas C, Williamson J, Hall DA, Rosenbaum M, Davis S, Dean M, Cromer C, Smith J, Ruffrage L, Richardson J, Sipma R, Padmanaban M, Warren N, Mercado T, Disbrow E, Chauppeta B, Thomas-Dean F, Toms J, Lofton K, Rawls A, Rizer K, Black N, Solle J, O'Grady A, Sherer T, Fiske B, Blauwendraat C, Okubadejo NU, Basak AN, Tan AH, Noyce A, Akpalu A, Espay A, Martinez-Carrasco A, Medina A, Zimprich A, Brice A, Karimova A, Hernandez A, Illarionova A, Quattrone A, Singleton AB, Sobering AK, Vinuela A, Sanyaolu A, Schumacher-Schuh AF, Kishore A, Ahmad-Annuar A, Al Mubarak B, Tang B, Pizarro Galleguillos B, Jeon B, Siddiqi B, Casey B, Mollenhauer B, Carroll C, Rieder C, Pantazis CB, Comart C, Lin C-H, Klein C, Bale C, Shepherd CE, Wegel C, Martinez-Ramirez D, Hall D, Hernandez D, KP D, Nguyen D, Fon EA, Dadiotis E, Riley E, Iakovenko E, Stafford E, Gatto EM, Valente EM, Vollstedt E-J, Faghri F, Genc G, Xiromerisiou G, Hadjigorgiou G, Hiu-Fai Chan G, Arboleda G, Kaishibayeva G, Hoglinger G, Leonard H, Madoev H, Chen H, Wu H-C, Shang H, F Mata I, Keller Sarmiento IJ, Dagklis I, Tarnanas I, Aasly JO, Hoenicka J, Corvol J-C, Foo JN, Guo J, Junker J, Carr J, Kim JJ, Orozco J, Jankovic J, Shulman J, Hunter J, Solle JC, Murphy K, Nuytemans K, Kieburtz K, Lohmann K, Marek K, Mok KY, Kumar K, Levine K, Chahine LM, Lange LM, Pihlstrom L, Screven L, Stefanis L, Shulman L, Marsili L, Parnetti L, Kuhl M, Funayama M, Sharma M, Tan M, Kauffman M, Miranda M, Bustamante ML, Stamelou M, Perinan Tocino MT, Cornejo-Olivas M, Jimenez del Rio M, Koretsky M, Rodriguez-Violante M, Ellis M, Avenali M, Renteria ME, Inca-Martines MZ, Nalls MA, Nalls MA, Ibrahim Norlinah M, Umair M, Ip N, Louie N, Cheung NY-F, Mencacci NE, Wood N, Williams N, Hattori N, Abdul Murad NA, Ibrahim NM, Monchi O, Oztop Cakmak O, Oztop Cakmak POC, Lewis PA, Pastor P, Reyes-Perez P, Saffie Awad P, Chana P, Chan P, Kung P-J, Chan P, Pal P, Lingappa Kukkle P, Ojha R, Kaiyrzhanov R, Kruger R, Amouri R, Weil R, Rajan R, Alcalay R, Wu R-M, Borgohain R, Sassi SB, Khachatryan S, El-Sadig S, Wu S, Groppa S, Azmin S, Lim S-Y, Ur-Rehman S, Ertan S, Stott S, Jasaitye S, Chowdhury S, Dumanis S, Bardien S, Lubbe S, Koks S, Dey S, Foroud T, Fon T, Beach T, Gasser T, Anderson T, Nguyen T, Schirinzi T, Shiraishi T, Pitcher T, Tumas V, Mohamed W, Kamel WA, Luo W, Zhou X, Zewde YZ, Song Y, Wen Y, Wu Y, Joong Kim Y, Tavadyan Z. Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study. The Lancet Neurology 2023, 22(11), 1015-1025.
    • Carrasco AM, Real R, Lawton M, Reynolds RH, Tan M, Wu L, Williams N, Carroll C, Corvol J-C, Hu M, Grosset D, Hardy J, Ryten M, Ben-Shlomo Y, Shoai M, Morris HR. Genome-wide Analysis of Motor Progression in Parkinson Disease. Neurology: Genetics 2023, 9(5), e200092.
    • Martinez-Carrasco A, Real R, Lawton M, Iwaki H, Tan MMX, Wu L, Williams NM, Carroll C, Hu MTM, Grosset DG, Hardy J, Ryten M, Foltynie T, Ben-Shlomo Y, Shoai M, Morris HR. Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease. npj Parkinson's Disease 2023, 9, 128.
    • Towns C, Richer M, Jasaityte S, Stafford EJ, Joubert J, Antar T, Martinez-Carrasco A, Makarious MB, Casey B, Vitale D, Levine K, Leonard H, Pantazis CB, Screven LA, Hernandez DG, Wegel CE, Solle J, Nalls MA, Blauwendraat C, Singleton AB, Tan MMX, Iwaki H, Morris HR, Gatto EM, Kauffman M, Khachatryan S, Tavadyan Z, Shepherd CE, Hunter J, Kumar K, Ellis M, Renteria ME, Koks S, Zimprich A, Schumacher-Schuh AF, Rieder C, Awad PS, Tumas V, Camargos S, Fon EA, Monchi O, Fon T, Galleguillos BP, Miranda M, Bustamante ML, Olguin P, Chana P, Tang B, Shang H, Guo J, Chan P, Luo W, Arboleda G, Orozco J, del Rio MJ, Hernandez A, Salama M, Kamel WA, Zewde YZ, Brice A, Corvol J-C, Westenberger A, Illarionova A, Mollenhauer B, Klein C, Vollstedt E-J, Hopfner F, Hoglinger G, Madoev H, Trinh J, Junker J, Lohmann K, Lange LM, Sharma M, Groppa S, Gasser T, Fang Z-H, Akpalu A, Xiromerisiou G, Hadjigorgiou G, Dagklis I, Tarnanas I, Stefanis L, Stamelou M, Dadiotis E, Medina A, Chan GH-F, Ip N, Cheung NY-F, Chan P, Zhou X, Kishore A, Kp D, Pal P, Kukkle PL, Rajan R, Borgohain R, Salari M, Quattrone A, Valente EM, Parnetti L, Avenali M, Schirinzi T, Funayama M, Hattori N, Shiraishi T, Karimova A, Kaishibayeva G, Shambetova C, Kruger R, Tan AH, Ahmad-Annuar A, Norlinah MI, Murad NAA, Azmin S, Lim S-Y, Mohamed W, Tay YW, Martinez-Ramirez D, Rodriguez-Violante M, Reyes-Perez P, Tserensodnom B, Ojha R, Anderson TJ, Pitcher TL, Sanyaolu A, Okubadejo N, Ojo O, Aasly JO, Pihlstrom L, Tan M, Ur-Rehman S, Cornejo-Olivas M, Doquenia ML, Rosales R, Vinuela A, Iakovenko E, Mubarak BA, Umair M, Tan E-K, Foo JN, Amod F, Carr J, Bardien S, Jeon B, Kim YJ, Cubo E, Alvarez I, Hoenicka J, Beyer K, Perinan MT, Pastor P, El-Sadig S, Zweier C, Krack P, Lin C-H, Wu H-C, Kung P-J, Wu R-M, Wu Y, Amouri R, Sassi SB, Basak AN, Genc G, Cakmak OO, Ertan S, Noyce A, Schrag A, Schapira A, Carroll C, Bale C, Grosset D, Houlden H, Hardy J, Mok KY, Rizig M, Wood N, Williams N, Okunoye O, Lewis PA, Kaiyrzhanov R, Weil R, Love S, Stott S, Jasaitye S, Dey S, Obese V, Espay A, O'Grady A, Sobering AK, Siddiqi B, Fiske B, Jonas C, Cruchaga C, Comart C, Wegel C, Hall D, Hernandez D, Shiamim E, Riley E, Faghri F, Serrano GE, Chen H, Mata IF, Sarmiento IJK, Williamson J, Kim JJ, Jankovic J, Shulman J, Solle JC, Murphy K, Nuytemans K, Kieburtz K, Markopoulou K, Marek K, Levine KS, Chahine LM, Ibanez L, Screven L, Ruffrage L, Shulman L, Marsili L, Kuhl M, Dean M, Koretsky M, Puckelwartz MJ, Inca-Martinez M, Louie N, Mencacci NE, Albin R, Alcalay R, Walker R, Bandres-Ciga S, Chowdhury S, Dumanis S, Lubbe S, Xie T, Foroud T, Beach T, Sherer T, Song Y, Nguyen D, Nguyen T, Atadzhanov M. Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2). npj Parkinson's Disease 2023, 9, 131.
    • Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, Bouchard M, Budur K, Carroll C, Chaudhuri KR, Criswell SR, Danielsen EH, Gandor F, Jia J, Kimber TE, Mochizuki H, Robieson WZ, Spiegel AM, Standaert DG, Talapala S, Facheris MF, Fung VSC. Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study. Neurology and Therapy 2023, 12(6), 1937-1958.
    • Sorrell L, Leta V, Barnett A, Stevens K, King A, Inches J, Kobylecki C, Walker R, Ray Chaudhuri K, Martin H, Rideout J, Robert Sneyd J, Campbell S, Carroll C. Clinical features and outcomes of hospitalised patients with COVID-19 and Parkinsonian disorders: A multicentre UK-based study. PLoS ONE 2023, 18(7), e0285349.
    • Kelly J, Moyeed R, Carroll C, Luo S, Li X. Blood biomarker-based classification study for neurodegenerative diseases. Scientific Reports 2023, 13, 17191.
    • Bounsall K, Milne-Ives M, Hall A, Carroll C, Meinert E. Artificial Intelligence Applications for Assessment, Monitoring, and Management of Parkinson Disease Symptoms: Protocol for a Systematic Review. JMIR Research Protocols 2023, 12, e46581.
    • Zeissler M-L, McFarthing K, Raphael KG, Rafaloff G, Windle R, Carroll CB. An International Multi-Stakeholder Delphi Survey Study on the Design of Disease Modifying Parkinson's Disease Trials. Journal of Parkinson's Disease 2023, 13(8), 1343-1356.
    • Russell J, Inches J, Carroll CB, Bergmann JHM. A modular, deep learning-based holistic intent sensing system tested with Parkinson’s disease patients and controls. Frontiers in Neurology 2023, 14, 1260445.
    • Meinert E, Milne-Ives M, Chaudhuri KR, Harding T, Whipps J, Whipps S, Carroll C. The Impact of a Digital Artificial Intelligence System on the Monitoring and Self-management of Nonmotor Symptoms in People With Parkinson Disease: Proposal for a Phase 1 Implementation Study. JMIR Research Protocols 2022, 11(9), e40317.
    • Schofield C, Chaudhuri KR, Carroll C, Sharma JC, Pavese N, Evans J, Foltynie T, Reichmann H, Zurowska L, Soares-Da-Silva P, Lees A. Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease. Neurodegenerative Disease Management 2022, 12(2), 77-91.
    • Stevens KN, Creanor S, Jeffery A, Whone A, Zajicek J, Foggo A, Jones B, Chapman R, Cocking L, Wilks J, Webb D, Carroll C. Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurology 2022, 79(12), 1232-1241.
    • Kehagia AA, North TK, Grose J, Jeffery AN, Cocking L, Chapman R, Carroll C. Enhancing Trial Delivery in Parkinson's Disease: Qualitative Insights from PD STAT. Journal of Parkinson's Disease 2022, 12(5), 1591-1604.
    • Day JO, Smith S, Noyce AJ, Alty J, Jeffery A, Chapman R, Carroll C. Challenges of Incorporating Digital Health Technology Outcomes in a Clinical Trial: Experiences from PD STAT. Journal of Parkinson's Disease 2022, 12(5), 1605-1609.
    • Schrag A, Carroll C, Duncan G, Molloy S, Grover L, Hunter R, Brown R, Freemantle N, Whipps J, Serfaty MA, Lewis G. Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson’s disease. BMC Neurology 2022, 22, 474.
    • Jost ST, Visser-Vandewalle V, Rizos A, Loehrer PA, Silverdale M, Evans J, Samuel M, Petry-Schmelzer JN, Sauerbier A, Gronostay A, Barbe MT, Fink GR, Ashkan K, Antonini A, Martinez-Martin P, Chaudhuri KR, Timmermann L, Dafsari HS, Bhidayasiri R, Falup-Pecurariu C, Jeon B, Leta V, Borghammer P, Odin P, Schrag A, Storch A, Violante MR, Weintraub D, Adler C, Barone P, Brooks DJ, Brown R, Cantillon M, Carroll C, Coelho M, Henriksen T, Hu M, Jenner P, Kramberger M, Kumar P, Kurtis M, Lewis S, Litvan I, Lyons K, Martino D, Masellis M, Mochizuki H, Morley JF, Nirenberg M, Pagonabarraga J, Panicker J, Pavese N, Pekkonen E, Postuma R, Rosales R, Schapira A, Simuni T, Stocchi F, Subramanian I, Tagliati M, Tinazzi M, Toledo J, Tsuboi Y, Walker R. Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease. npj Parkinson's Disease 2021, 7, 48.
    • Vijiaratnam N, Girges C, Auld G, Chau M, MacLagan K, King A, Skene SS, Chowdhury K, Hibbert S, Morris H, Limousin P, Athauda D, Carroll C, Hu MT, Silverdale M, Duncan GW, Chaudhuri R, Lo C, Del Din S, Yarnall AJ, Rochester L, Gibson R, Dickson J, Hunter R, Libri V, Foltynie T. Exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease: protocol for a multi-centre, randomised, double blind, parallel group, placebo controlled, Phase 3 trial, The 'Exenatide-PD3' study. BMJ Open 2021, 11(5), e047993.
    • Eke CS, Jammeh E, Li X, Carroll C, Pearson S, Ifeachor E. Early Detection of Alzheimer's Disease with Blood Plasma Proteins Using Support Vector Machines. IEEE Journal of Biomedical and Health Informatics 2021, 25(1), 218-226.

  • Conference Proceedings (inc. Abstract)

  • Letter

    • Lazaro-Figueroa A, Hernandez-Medrano AJ, Ramirez-Pineda DB, Cadavid AN, Makarious M, Foo JN, Alvarado CX, Bandres-Ciga S, Perinan MT, Gatto EM, Kauffman M, Khachatryan S, Tavadyan Z, Shepherd CE, Hunter J, Kumar K, Ellis M, Renteria ME, Koks S, Zimprich A, Schumacher-Schuh AF, Rieder C, Awad PS, Tumas V, Camargos S, Fon EA, Monchi O, Fon T, Galleguillos BP, Miranda M, Bustamante ML, Olguin P, Chana P, Tang B, Shang H, Guo J, Chan P, Luo W, Arboleda G, Orozco J, Del Rio MJ, Hernandez A, Salama M, Kamel WA, Zewde YZ, Brice A, Corvol J-C, Westenberger A, Illarionova A, Mollenhauer B, Klein C, Vollstedt E-J, Hopfner F, Hoglinger G, Madoev H, Trinh J, Junker J, Lohmann K, Lange LM, Sharma M, Groppa S, Gasser T, Fang Z-H, Akpalu A, Xiromerisiou G, Hadjigorgiou G, Dagklis I, Tarnanas I, Stefanis L, Stamelou M, Dadiotis E, Medina A, Chan GH-F, Ip N, Cheung NY-F, Chan P, Zhou X, Kishore A, Divya KP, Pal P, Kukkle PL, Rajan R, Borgohain R, Salari M, Quattrone A, Valente EM, Parnetti L, Avenali M, Schirinzi T, Funayama M, Hattori N, Shiraishi T, Karimova A, Kaishibayeva G, Shambetova C, Kruger R, Tan AH, Ahmad-Annuar A, Norlinah MI, Abdul Murad NA, Ibrahim NM, Azmin S, Lim S-Y, Mohamed W, Tay YW, Martinez-Ramirez D, Rodriguez-Violante M, Reyes-Perez P, Tserensodnom B, Ojha R, Anderson TJ, Pitcher TL, Sanyaolu A, Okubadejo N, Ojo O, Aasly JO, Pihlstrom L, Tan M, Ur-Rehman S, Cornejo-Olivas M, Doquenia ML, Rosales R, Vinuela A, Iakovenko E, Mubarak BA, Umair M, Tan E-K, Amod F, Carr J, Bardien S, Jeon B, Kim YJ, Cubo E, Alvarez I, Hoenicka J, Beyer K, Pastor P, El-Sadig S, Brolin K, Zweier C, Paul K, Lin C-H, Wu H-C, Kung P-J, Wu R-M, Wu S, Wu Y, Amouri R, Sassi SB, Nazli Basak A, Genc G, Cakmak OO, Ertan S, Noyce A, Martinez-Carrasco A, Schrag A, Schapira A, Carroll C, Bale C, Grosset D, Stafford EJ, Houlden H, Morris HR, Hardy J, Mok KY, Rizig M, Wood N, Williams N, Okunoye O, Lewis PA, Kaiyrzhanov R, Weil R, Love S, Stott S, Jasaityte S, Dey S, Obese V, Espay A, O'Grady A, Singleton AB, Sobering AK, Siddiqi B, Casey B, Fiske B, Jonas C, Cruchaga C, Pantazis CB, Comart C, Wegel C, Blauwendraat C, Vitale D, Hall D, Hernandez D, Shiamim E, Riley E, Faghri F, Serrano GE, Leonard H, Iwaki H, Chen H, Mata IF, Keller Sarmiento IJ, Williamson J, Kim JJ, Jankovic J, Shulman J, Solle JC, Murphy K, Nuytemans K, Kieburtz K, Markopoulou K, Marek K, Levine KS, Chahine LM, Screven L, Ruffrage L, Shulman L, Marsili L, Kuhl M, Dean M, Makarious MB, Koretsky M, Inca-Martinez M, Nalls MA, Louie N, Mencacci NE, Albin R, Alcalay R, Walker R, Chowdhury S, Dumanis S, Lubbe S, Xie T, Foroud T, Beach T, Sherer T, Song Y, Nguyen D, Nguyen T, Atadzhanov M. Is SH3GL2 p.G276V the Causal Functional Variant Underlying Parkinson's Disease Risk at this Locus?. Movement Disorders 2024, 39(11), 2117-2119.

  • Notes

    • Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, Bouchard M, Budur K, Carroll C, Chaudhuri KR, Criswell SR, Danielsen EH, Gandor F, Jia J, Kimber TE, Mochizuki H, Robieson WZ, Spiegel AM, Standaert DG, Talapala S, Facheris MF, Fung VSC. Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study (Neurology and Therapy, (2023), 12, 6, (1937-1958), 10.1007/s40120-023-00533-1). Neurology and Therapy 2023, 12(6), 1959-1960.
    • Lange LM, Ellis M, Keller Sarmiento IJ, Tan A-H, Galandra C, Roopnarain K, Solle J, Fang Z-H, Heutink P, Kumar KR, Lim S-Y, Valente EM, Nalls M, Singleton A, Mencacci N, Klein C, Gatto EM, Kauffman M, Khachatryan S, Tavadyan Z, Shepherd CE, Hunter J, Kumar K, Ellis M, Renteria ME, Koks S, Zimprich A, Schumacher-Schuh AF, Rieder C, Awad PS, Tumas V, Camargos S, Fon EA, Monchi O, Fon T, Galleguillos BP, Miranda M, Bustamante ML, Olguin P, Chana P, Tang B, Shang H, Guo J, Chan P, Luo W, Arboleda G, Orozco J, del Rio MJ, Hernandez A, Salama M, Kamel WA, Zewde YZ, Brice A, Corvol J-C, Westenberger A, Illarionova A, Illarionova A, Mollenhauer B, Klein C, Vollstedt E-J, Hopfner F, Hoglinger G, Madoev H, Madoev H, Trinh J, Junker J, Junker J, Lohmann K, Lohmann K, Lange LM, Sharma M, Groppa S, Gasser T, Fang Z-H, Akpalu A, Xiromerisiou G, Hadjigorgiou G, Dagklis I, Tarnanas I, Stefanis L, Stamelou M, Dadiotis E, Medina A, Chan GH-F, Ip N, Cheung NY-F, Chan P, Zhou X, Kishore A, Kp D, Pal P, Kukkle PL, Rajan R, Borgohain R, Salari M, Quattrone A, Valente EM, Parnetti L, Avenali M, Avenali M, Schirinzi T, Funayama M, Hattori N, Shiraishi T, Karimova A, Kaishibayeva G, Shambetova C, Kruger R, Ahmad-Annuar A, Norlinah MI, Murad NAA, Ibrahim NM, Azmin S, Lim S-Y, Mohamed W, Tay YW, Martinez-Ramirez D, Rodriguez-Violante M, Reyes-Perez P, Tserensodnom B, Ojha R, Anderson TJ, Pitcher TL, Sanyaolu A, Okubadejo N, Ojo O, Aasly JO, Pihlstrom L, Tan M, Ur-Rehman S, Cornejo-Olivas M, Doquenia ML, Rosales R, Vinuela A, Iakovenko E, Mubarak BA, Umair M, Tan E-K, Foo JN, Amod F, Carr J, Bardien S, Jeon B, Kim YJ, Cubo E, Alvarez I, Hoenicka J, Beyer K, Perinan MT, Pastor P, El-Sadig S, Zweier C, Paul K, Lin C-H, Wu H-C, Kung P-J, Wu R-M, Wu S, Wu Y, Amouri R, Sassi SB, Basak AN, Genc G, Cakmak OO, Ertan S, Noyce A, Martinez-Carrasco A, Schrag A, Schapira A, Carroll C, Bale C, Grosset D, Stafford EJ, Houlden H, Morris HR, Hardy J, Mok KY, Rizig M, Wood N, Williams N, Okunoye O, Lewis PA, Kaiyrzhanov R, Weil R, Love S, Stott S, Jasaitye S, Dey S, Obese V, Espay A, O'Grady A, Singleton AB, Sobering AK, Siddiqi B, Casey B, Fiske B, Jonas C, Cruchaga C, Pantazis CB, Comart C, Wegel C, Wegel C, Blauwendraat C, Blauwendraat C, Vitale D, Hall D, Hernandez D, Shiamim E, Riley E, Faghri F, Serrano GE, Leonard H, Iwaki H, Chen H, Mata IF, Sarmiento IJK, Williamson J, Kim JJ, Jankovic J, Shulman J, Solle JC, Murphy K, Nuytemans K, Kieburtz K, Markopoulou K, Marek K, Levine KS, Chahine LM, Screven L, Ruffrage L, Shulman L, Marsili L, Kuhl M, Dean M, Makarious MB, Koretsky M, Inca-Martinez M, Nalls MA, Louie N, Mencacci NE, Albin R, Alcalay R, Walker R, Bandres-Ciga S, Chowdhury S, Dumanis S, Lubbe S, Xie T, Foroud T, Beach T, Sherer T, Song Y, Nguyen D, Nguyen T, Atadzhanov M. Author Correction: Elucidating causative gene variants in hereditary Parkinson’s disease in the Global Parkinson’s Genetics Program (GP2) (npj Parkinson's Disease, (2023), 9, 1, (100), 10.1038/s41531-023-00526-9). npj Parkinson's Disease 2023, 9(1), 133.
    • Rochester L, Carroll C. Implications of research that excludes under-served populations. Nature Reviews Neurology 2022, 18, 449-450.
    • Masoli JAH, Down K, Nestor G, Hudson S, O'Brien JT, Williamson JD, Young CA, Carroll C. A report from the NIHR UK working group on remote trial delivery for the COVID-19 pandemic and beyond. Trials 2021, 22(1), 911.

  • Reviews